Terms: = Liver cancer AND CTLA4, ALPS5, CD, CD152, CELIAC3, CTLA-4, GRD4, GSE, IDDM12 AND Diagnosis
174 results:
1. Clinical Phenotype and Disease Course of Inflammatory Bowel Disease in Iran: Results of the Iranian Registry of Crohn's and Colitis (IRCC).
Saberzadeh-Ardestani B; Khosravi AA; Mansour-Ghanaei F; Vahedi H; Baniasadi N; Seyyedmajidi M; Parhizkar B; Hormati A; Naghshbandi SJ; Matin S; Hassan Zadeh AA; Taghvaei T; Bahrami M; Rafeey M; Ahadi M; Vossoughinia H; Muosavi H; Gheibi S; Hosseini-Hemmatabadi RS; Yazdanbod A; Matinkhah S; Sheikh Esmaeili F; Fakheri H; Moosavy SH; Maleki I; Nasseri-Moghaddam S; Khosravi B; Farahmand F; Najafi M; Alimadadi H; Malekzadeh M; Anushiravani A; Kasaeian A; Alatab S; Sadeghi A; Radmard AR; Kolahdoozan S; Rajabi Z; Sima AR
Arch Iran Med; 2024 Apr; 27(4):183-190. PubMed ID: 38685844
[TBL] [Abstract] [Full Text] [Related]
2. An algorithm based on immunotherapy discontinuation and liver biopsy spares corticosteroids in two thirds of cases of severe checkpoint inhibitor-induced liver injury.
Riveiro-Barciela M; Barreira-Díaz A; Salcedo MT; Callejo-Pérez A; Muñoz-Couselo E; Iranzo P; Ortiz-Velez C; Cedrés S; Díaz-Mejía N; Ruiz-Cobo JC; Morales R; Aguilar-Company J; Zamora E; Oliveira M; Sanz-Martínez MT; Viladomiu L; Martínez-Gallo M; Felip E; Buti M
Aliment Pharmacol Ther; 2024 Apr; 59(7):865-876. PubMed ID: 38327102
[TBL] [Abstract] [Full Text] [Related]
3. Bioinformatic Analysis and Computer-Aided Study to Investigate the Potential Application of a Bioflavonoid Compound Bilobetin in liver cancer Treatment.
Zhang C; Sui Y; Liu S; Yang M
Front Biosci (Landmark Ed); 2023 Dec; 28(12):360. PubMed ID: 38179744
[TBL] [Abstract] [Full Text] [Related]
4. Real-world management practices and characteristics of patients with advanced melanoma initiated on immuno-oncology or targeted therapy in the first-line setting during the period 2015-2018 in Greece. The 'SUMMER' study: a retrospective multicenter chart review project.
Bafaloukos D; Kouzis P; Gouveris P; Boukovinas I; Kalbakis K; Baka S; Kyriakakis G; Moschou D; Molfeta A; Demiri S; Mavroudis D; Spanoudi F; Dimitriadis I; Gogas H
Melanoma Res; 2024 Apr; 34(2):152-165. PubMed ID: 38092014
[TBL] [Abstract] [Full Text] [Related]
5. [Multimodal ultrasound techniques for the differential diagnosis of splenic lesions - A diagnostic challenge].
Stock KF; Slotta-Huspenina J; Findeisen H; Görg C
Chirurgie (Heidelb); 2023 Dec; 94(12):1000-1008. PubMed ID: 38010420
[TBL] [Abstract] [Full Text] [Related]
6. Elevated liver Fibrosis Progression in Isolated PSC Patients and Increased Malignancy Risk in a PSC-IBD Cohort: A Retrospective Study.
Rennebaum F; Demmig C; Schmidt HH; Vollenberg R; Tepasse PR; Trebicka J; Gu W; Ullerich H; Kabar I; Cordes F
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895106
[TBL] [Abstract] [Full Text] [Related]
7. Disparities in outcomes and access to therapy options in hepatocellular carcinoma.
Beltrán Ponce S; Gokun Y; Douglass F; Dawson L; Miller E; Thomas CR; Pitter K; Conteh L; Diaz DA
J Natl Cancer Inst; 2024 Feb; 116(2):264-274. PubMed ID: 37831897
[TBL] [Abstract] [Full Text] [Related]
8. Tocilizumab in grade 4 hepatitis secondary to immune checkpoint inhibitor: a case report and review of the literature.
Ali SB; Vembar P; Sukumaran S; Gunawardane D; Hughes T; Smith A
Immunotherapy; 2023 Oct; 15(14):1125-1132. PubMed ID: 37401340
[TBL] [Abstract] [Full Text] [Related]
9. Autoimmune Pancreatitis in Patients with Inflammatory Bowel Disease: A Real-World Multicentre Collaborative ECCO CONFER Study.
Eder P; Verstock B; Culver E; Dragoni G; Kredel LI; Wypych J; de Paredes AGG; Kaniewska M; Leibovitzh H; Lobaton T; Truyens M; Oracz G; Ribaldone DG; Starzyńska T; Badaoui A; Rahier JF; Bezzio C; Bossuyt P; Falloon K; Pugliese D; Frakes Vozzo C; Jess T; Larsen L; Olesen SS; Pal P; Chaparro M; Dror D; Ellul P; Gromny I; Janiak M; Maciejewska K; Peleg N; Bar-Gil Shitrit A; Szwed Ł; Talar-Wojnarowska R; Snir Y; Weisshof R; Zittan E; Miechowicz I; Goren I
J Crohns Colitis; 2023 Nov; 17(11):1791-1799. PubMed ID: 37283545
[TBL] [Abstract] [Full Text] [Related]
10. MESP1-knockdown inhibits the proliferation and epithelial mesenchymal transition of hepatocellular carcinoma and enhances the tumor-suppressive effect of 5-fluorouracil.
Ji S; Xu M; Cai C; He X
Biochem Biophys Res Commun; 2023 Aug; 670():1-11. PubMed ID: 37271034
[TBL] [Abstract] [Full Text] [Related]
11. Elevated Serum and Hair Levels of Cadmium as a Risk Factor for liver Carcinoma: A Meta-Analysis.
Zhang L; Wang Y; Li T; Zhuo W; Zhu Y
Nutr Cancer; 2023; 75(6):1438-1447. PubMed ID: 37203428
[TBL] [Abstract] [Full Text] [Related]
12. Immunotherapy for recurrent hepatocellular carcinoma.
Bhatt A; Wu J
World J Gastroenterol; 2023 Apr; 29(15):2261-2271. PubMed ID: 37124885
[TBL] [Abstract] [Full Text] [Related]
13. Hemophagocytic lymphohistiocytosis in inflammatory bowel disease: a nationwide analysis.
Mahmoud AA; Abdelhay A; Khamis A; Mostafa M; Shehadah A; Mohamed MS; Eltaher B; Malik T
Ann Hematol; 2023 Jul; 102(7):1705-1711. PubMed ID: 37093242
[TBL] [Abstract] [Full Text] [Related]
14. HAMP as a Potential Diagnostic, PD-(L)1 Immunotherapy Sensitivity and Prognostic Biomarker in Hepatocellular Carcinoma.
Chen G; Zhang C; Li D; Luo D; Liao H; Huang P; Wang N; Feng Y
Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830729
[TBL] [Abstract] [Full Text] [Related]
15. Three cases of immune-related hypopituitarism after atezolizumab-bevacizumab treatment for hepatocellular carcinoma.
Furuichi N; Naganuma A; Kaburagi T; Suzuki Y; Hoshino T; Shibusawa N; Horiguchi S; Hatanaka T; Kakizaki S; Uraoka T
Clin J Gastroenterol; 2023 Jun; 16(3):422-431. PubMed ID: 36821067
[TBL] [Abstract] [Full Text] [Related]
16. Impact of Crohn's Disease on the Survival of Patients with Small-Bowel Adenocarcinoma in Korea: A Bicenter Cohort Study.
Kim K; Choi K; Hwang SW; Im JP; Ye BD; Kim JS; Park KJ; Yang SK; Koh SJ; Park SH;
Gut Liver; 2023 Jul; 17(4):581-590. PubMed ID: 36510777
[TBL] [Abstract] [Full Text] [Related]
17. Metabolic effects of long-term cadmium exposure: an overview.
Chen XX; Xu YM; Lau ATY
Environ Sci Pollut Res Int; 2022 Dec; 29(60):89874-89888. PubMed ID: 36367641
[TBL] [Abstract] [Full Text] [Related]
18. LOXL2 serves as a prognostic biomarker for hepatocellular carcinoma by mediating immune infiltration and vasculogenic mimicry.
Zhao N; Chen C; Guo Y; Liu T; Che N; Zhang D; Liang X; Zhang Y; Zhao X
Dig Liver Dis; 2023 May; 55(5):661-672. PubMed ID: 36192339
[TBL] [Abstract] [Full Text] [Related]
19. Targeting Tumor Microenvironment in liver cancers: Rationale, Current Progress, and Future Perspective.
Duda DG
Keio J Med; 2022; 71(3):71. PubMed ID: 36155490
[TBL] [Abstract] [Full Text] [Related]
20. Hepatocellular carcinoma (HCC) in patients with Non-Alcoholic Fatty liver Disease (NAFLD): screening, treatment and survival analysis in a Brazilian series.
Alencar RSSM; Oliveira CP; Chagas AL; Fonseca LGD; Maccali C; Saud LRDC; Xerfan MP; Stefano JT; Herman P; D'Albuquerque LAC; Alves VAF; Carrilho FJ
Clinics (Sao Paulo); 2022; 77():100097. PubMed ID: 36088887
[TBL] [Abstract] [Full Text] [Related]
[Next]
